PCN21 Comparative Effectiveness and Cost-Effectiveness Assessment of Erlotinib Versus Gefitinib in First-Line Treatment of EGFR Activating Mutation Positive Non-Small Cell Lung Cancer for Hong Kong
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.318
https://www.valueinhealthjournal.com/article/S1098-3015(12)02031-1/fulltext
Title :
PCN21 Comparative Effectiveness and Cost-Effectiveness Assessment of Erlotinib Versus Gefitinib in First-Line Treatment of EGFR Activating Mutation Positive Non-Small Cell Lung Cancer for Hong Kong
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02031-1&doi=10.1016/j.jval.2012.08.318
First page :
A656
Section Title :
Cancer
Open access? :
No
Section Order :
1857